SIGA Technologies Reports Worsened Q1 Loss, Revenues Decline

summarizeSummary

SIGA Technologies reported a significant increase in net loss and a decrease in revenues for Q1 2026 compared to the prior year, alongside updates on TPOXX deliveries and a new international license agreement.

check_boxKey Events

• Q1 Net Loss Worsens Significantly

  The company reported a net loss of $3.5 million for Q1 2026, a substantial increase from a $0.4 million net loss in Q1 2025. Diluted loss per share worsened to $0.05 from $0.01.

• Revenues Decline Year-over-Year

  Total revenues decreased to $6.2 million in Q1 2026 from $7.0 million in Q1 2025, driven by lower product sales.

• Future TPOXX Deliveries Confirmed

  SIGA expects to deliver $13 million of oral TPOXX to an international customer in Q2 2026 and $26 million of IV TPOXX to the U.S. Government Strategic National Stockpile by the end of Q3 2026.

• New International License Agreement

  In March 2026, SIGA entered an exclusive license agreement with Hikma MENA FZE for oral TPOXX commercialization in the Middle East and North Africa region.

auto_awesomeAnalysis

The company's first-quarter financial results show a substantial deterioration in profitability, with net loss increasing from $0.4 million to $3.5 million year-over-year and diluted loss per share worsening from $0.01 to $0.05. This negative financial performance is a key concern for investors. While the company provided updates on expected TPOXX deliveries and a new international license agreement, these positive developments are overshadowed by the current quarter's financial decline. Investors should monitor future revenue recognition from the announced deliveries and the impact of the MENA agreement on long-term growth.